Cancer Immunotherapy or CAR-T Cell Therapy Denied by Insurance? Here's How to Appeal

A cancer diagnosis is one of the most difficult experiences a person can face. An insurance denial for immunotherapy or CAR-T cell therapy compounds that burden enormously — these treatments are often life-extending or potentially curative for patients who have exhausted other options, and denial delays treatment at a time when time directly affects outcomes. Checkpoint inhibitors, CAR-T therapies, and bispecific antibodies have transformed oncology over the past decade, and the clinical evidence supporting their use is among the most robust in all of medicine. This guide explains why these denials happen, what the law requires, and how to build an effective appeal.

Why Insurers Deny Cancer Immunotherapy and CAR-T Therapy

"Experimental or investigational" classification. The most consequential and most prevalent denial type. Insurers apply their own internal clinical policy bulletins to classify FDA-approved checkpoint inhibitors (pembrolizumab/Keytruda, nivolumab/Opdivo, atezolizumab/Tecentriq, durvalumab/Imfinzi), CAR-T therapies (axicabtagene ciloleucel/Yescarta, tisagenlecleucel/Kymriah, lisocabtagene maraleucel/Breyanzi, ciltacabtagene autoleucel/Carvykti), and bispecific antibodies (epcoritamab/Epkinly, glofitamab/Columvi) as "experimental" despite their FDA approval status and NCCN guideline support. These internal policy bulletins may lag years behind FDA approval dates.

Off-label use denials. Oncologists routinely use FDA-approved immunotherapy agents for cancer types beyond the initial labeled indication when NCCN guidelines support the use. An insurer may cover pembrolizumab for first-line non-small cell lung cancer (NSCLC) with PD-L1 TPS ≥ 50% but deny it for the same patient's use under a Category 2A NCCN recommendation for a related indication. NCCN guidelines — not FDA labels alone — define the clinical standard of care in oncology.

Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization denials. All immunotherapy and CAR-T treatments require prior authorization. Denials occur when the oncologist's documentation doesn't precisely align with the insurer's internal PA criteria, when biomarker results are not submitted with sufficient specificity, or when the NCCN recommendation category is not explicitly cited.

Step therapy requirements. Some insurers require patients to fail on conventional chemotherapy before approving immunotherapy first-line, even when tumor biology — high PD-L1 expression (TPS ≥ 50%), MSI-H/dMMR status, high TMB, or specific driver mutations — clinically supports immunotherapy as the optimal first-line approach per NCCN guidelines.

CAR-T site-of-service and authorization disputes. CAR-T therapies are complex, FDA-regulated cellular therapies administered only at FDA-authorized treatment centers. Insurers may require specific pre-certification of the administering center, deny claims citing out-of-network issues with the authorized center, or object to the leukapheresis and manufacturing steps as separate billable events. Each step in the CAR-T process requires its own documentation and authorization strategy.

How to Appeal a Cancer Immunotherapy or CAR-T Denial

Step 1: Obtain the Full Denial with Internal Clinical Criteria

Request the complete denial letter and the specific clinical policy bulletin or coverage criteria the insurer applied. For ERISA employer plans (29 U.S.C. § 1133), you are entitled to all documents material to the claim decision. For any non-grandfathered plan under ACA Section 2719, you are entitled to the specific clinical criteria and the identity of the reviewer. The gap between the insurer's internal criteria and FDA approval with NCCN guideline support is typically the core of a successful appeal.

Step 2: Match Your Diagnosis to FDA Approval or NCCN Guideline Precisely

Obtain your complete pathology report including tumor type, stage, histologic subtype, and all molecular and biomarker results: PD-L1 expression (TPS and CPS where applicable), MSI-H/dMMR status, tumor mutational burden (TMB-H defined as ≥ 10 mut/Mb), HER2 status, BRAF/KRAS/EGFR mutation status, and any other relevant biomarkers. Match these precisely to the FDA-approved indication or NCCN guideline recommendation. The more exactly you can align your tumor's molecular profile to the approved or recommended indication, the stronger your appeal.

Step 3: Obtain a Comprehensive Letter from Your Oncologist

Your oncologist's letter must document: your specific cancer diagnosis with ICD-10 code; all relevant molecular markers and biomarker testing results; why the requested therapy is the most clinically appropriate option given your tumor biology; what prior treatments have been administered and their outcomes; and specific citation of the NCCN guideline recommendation category supporting the requested therapy (Category 1: high-level evidence, uniform NCCN consensus; Category 2A: lower-level evidence, uniform consensus). The letter must directly address the insurer's stated denial reason.

Step 4: Counter "Experimental" Denial with FDA Approval Evidence

If denied as experimental: gather the FDA approval letter and current prescribing information for the specific therapy; identify the precise FDA-approved indication statement that matches your diagnosis and molecular profile; obtain the NCCN Guideline pages showing the Category 1 or 2A recommendation for your specific indication; and cite pivotal clinical trial publications (KEYNOTE series for pembrolizumab, CheckMate series for nivolumab, ZUMA-1/7 for Yescarta, JULIET for Kymriah, TRANSCEND for Breyanzi). FDA approval directly contradicts experimental classification — these are not mutually compatible designations.

Step 5: Request Urgent Peer-to-Peer Review

Have your oncologist request an urgent peer-to-peer review with the insurer's medical director. Oncologist-to-oncologist conversations about FDA-approved, NCCN Category 1-supported therapies frequently resolve denials before formal appeal — particularly when the clinical urgency of cancer treatment is clearly communicated. If the denied service is urgent, request an expedited review and document the medical urgency in writing.

Step 6: File Internal Appeal and Immediately Escalate to External Independent Review: Complete Guide" class="auto-link">External Review

Submit within 180 days of denial (sooner if clinically urgent). Include: oncologist's letter, complete pathology and biomarker reports, NCCN guideline excerpts for your cancer type, FDA approval label, pivotal trial publications, prior treatment history, and state off-label drug mandate citations if applicable. More than 40 states require coverage of off-label cancer drug use supported by NCCN guidelines and standard oncology compendia. Request review by a board-certified oncologist with expertise in your cancer type. If internal appeal fails, file immediately for independent external review — external reviewers apply NCCN guidelines and FDA standards, not insurer internal bulletins.

What to Include in Your Appeal

• Denial letter with specific stated reasons and clinical policy bulletin or criteria cited
• Complete pathology report with tumor type, grade, stage, and all molecular and biomarker results (with ICD-10 codes)
• Oncologist's comprehensive letter of medical necessity with NCCN category citation
• NCCN Guideline pages showing Category 1 or 2A recommendation for your specific indication
• FDA approval label for the requested therapy with the specific indication that matches your diagnosis
• Pivotal clinical trial publications supporting efficacy in your indication
• Prior treatment history and outcomes
• State off-label drug mandate or cancer clinical trial coverage law if applicable

Fight Back With ClaimBack

External reviews of cancer immunotherapy and CAR-T denials involving FDA-approved therapies and NCCN Category 1 support are overturned at meaningful rates. Insurers know that denying FDA-approved cancer treatment supported by NCCN consensus carries significant clinical, legal, and reputational risk. ClaimBack generates a professional appeal letter in 3 minutes, citing the specific NCCN recommendations, FDA approvals, and federal regulations that apply to your immunotherapy or CAR-T denial. Start your free claim analysis → Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal